Delstrigo is a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg). Pifeltro (doravirine, 100mg) is a new non-nucleoside reverse transcriptase
Adapt Pharma is a privately-held company committed to expanding affordable access to Narcan (naloxone HCI) nasal spray and to progressing treatment options in the field of addiction. The
Onvansertib is a first-in-class, third generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor. Trovagene executive chairman Dr Thomas Adams said: “The European Commission’s decision to grant orphan
The study results, as well as the results of Sonoma’s previous HOCl acne studies (total of 127 patients), were presented by the principal investigator, Mark Steven Nestor, M.D.,
As part of the deal, Affimed will authorize its redirected optimized cell killing (ROCK) platform to discover and optimize innate immune cell engager-based immunotherapeutics of interest to Genentech.
Harbour BioMed is engaged in the discovery and development of therapeutics for oncology and immunological diseases. The financing round was led by GIC Private Limited, and participants included
Xerava has been developed for the treatment of cIAI in patients 18 years of age and older. In clinical trials, Xerava has showed statistical non-inferiority to two widely
The company has secured approval from the Food and Drug Administration for drugs with strengths of 3 mg/0.02 mg/0.451 mg and 0.451 mg (EQ Beyaz). Lupin’s Drospirenone, Ethinyl
The EU approval is based on data from the COMPASS study, the largest phase III study with rivaroxaban (27,395 patients), which showed that the rivaroxaban vascular dose, 2.5mg
M Ventures, the strategic, corporate venture arm of Merck KGaA, Darmstadt, Germany, and existing investors provided an additional $4m in the company’s Series A. Concurrent with the financing,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.